FDA Brief

Warning letters Food

FDA warning letter to

Richardson Nutritional Center, LLC/Nutriseeds, Inc.

High riskIssued Feb 19, 2021Posted Jun 1, 2021Office of Human and Animal Food Operations-West Division 5

FDA told Richardson Nutritional Center and Nutriseeds that their apricot seed, amygdalin and laetrile products are unapproved new drugs promoted with disease claims.

What happened

FDA reviewed the company's websites (nutriseeds.com, californiaapricotseeds.com, rncstore.com) in January 2021, along with an eBook titled "Apricot Seeds and B17: What You Need to Know" and a YouTube channel. FDA found claims that the products treat cancer, asthma, bronchitis, arthritis, high blood pressure, constipation and other conditions, which makes them drugs in FDA's view. There was no inspection; the findings came from the website, eBook and video review.

What FDA found

  1. The websites, eBook and YouTube channel claim the products cure, treat or prevent disease, so FDA treats them as drugs.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are not generally recognized as safe and effective for these uses, so they are new drugs that need FDA approval before sale.

    sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The products do not carry adequate directions for use, because a layperson cannot safely use them for the claimed diseases without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5
  4. Selling these misbranded drugs across state lines violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks the company to write back within fifteen working days describing the specific steps taken to correct the violations, with supporting documents, or to explain why it believes the products are compliant.

Who should pay attention

  • retailers and online marketplaces listing apricot seed or laetrile-type supplements
  • supplement brands that make disease or cancer claims on websites, eBooks or YouTube
  • marketers who use testimonials and videos to promote supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk